US News

Avacta pauses sales of COVID-19 antigen test to improve Omicron sensitivity

Published by

By Amna Karimi and Pushkala Aripaka (Reuters) -Britain’s Avacta Group is halting sales of its COVID-19 rapid antigen lateral flow test to replace antibodies in the device and boost its ability to detect the Omicron variant, the biotech firm said on Monday, sending its shares plunging nearly 27%. The London-listed company’s test, AffiDX, can detect the Omicron variant when the virus is present in high numbers in samples, but tests carried out by Avacta found AffiDX is less sensitive to Omicron at lower viral loads versus other variants. Scientists and governments are scrambling to bolster defen…

Read More

Facebook Comments

Check Also

Bitcoin Mining Company GRIID to Be First Recipient of Intel's “Bonanza Mine” Chips

  GRIID, an American infrastructure company that owns ...